SIRONA 3-Year Results: Sirolimus-Coated Balloon Shows Higher Freedom From Repeat Revascularization Than Paclitaxel-Coated Balloons in Femoropopliteal Disease

 Late-breaking data presented at TCT 2026 and published simultaneously in JACC: Cardiovascular Interventions show durable benefit with MagicTouch PTA, with similar walking capacity, quality of life and safety in both groups TAMPA, Fla., Nov. 3, 2026 /PRNewswire/ -- Three-year results from the randomized SIRONA trial show that patients with femoropopliteal artery disease treated with the MagicTouch PTA (Concept Medical) sirolimus-coated balloon (SCB) were more often free from clinically driven target lesion revascularization (cdTLR) than those treated with paclitaxel-coated balloons (…READ FULL ARTICLE